Radioprotectors and Mitigators of Radiation-Induced Normal Tissue Injury
Radioprotectors and Mitigators of Radiation-Induced Normal Tissue Injury
复制标题
DOI：
10.1634/theoncologist.2009-s104
复制
发表时间：
2010-01-01
期刊：
影响因子：
5.8
通讯作者：
Mitchell, James B.
中科院分区：
文献类型：
--
作者：
Citrin, Deborah;Cotrim, Ana P.;Mitchell, James B.
放射用于治疗多种恶性肿瘤。正常组织暴露于辐射可能会导致急性和慢性毒性，从而导致无法提供预期治疗、出现一系列症状以及生活质量下降。辐射防护剂是旨在减少辐射对正常组织造成的损伤的化合物。这些化合物通常是抗氧化剂，必须在辐射之前或辐射时存在才能发挥作用。即使在放射治疗之后，也可以使用其他药物（称为缓解剂）将毒性降至最低。在此，我们回顾了临床使用或正在开发的作为辐射引起的正常组织损伤的辐射防护剂和缓解剂的药物。很少有药物被批准用于临床，但许多新化合物在临床前测试中显示出有希望的结果。肿瘤学家 2010； 15：360-371
Radiation is used in the treatment of a broad range of malignancies. Exposure of normal tissue to radiation may result in both acute and chronic toxicities that can result in an inability to deliver the intended therapy, a range of symptoms, and a decrease in quality of life. Radioprotectors are compounds that are designed to reduce the damage in normal tissues caused by radiation. These compounds are often antioxidants and must be present be-fore or at the time of radiation for effectiveness. Other agents, termed mitigators, may be used to minimize toxicity even after radiation has been delivered. Herein, we review agents in clinical use or in development as radioprotectors and mitigators of radiation-induced normal tissue injury. Few agents are approved for clinical use, but many new compounds show promising results in preclinical testing. The Oncologist 2010; 15: 360-371